Meeting
2021 ASCO Annual Meeting
A phase I trial of plinabulin in combination with nivolumab and ipilimumab in patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study.
Authors
Jyoti Malhotra
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Jyoti Malhotra , Nasser H. Hanna , Alberto Chiappori , Lawrence Eric Feldman , Naomi Fujioka , Igor I. Rybkin , Shadia Ibrahim Jalal , Malini Patel , Dirk Moore , Chunxia Chen , Salma K. Jabbour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03575793
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8570)
DOI
10.1200/JCO.2021.39.15_suppl.8570
Abstract #
8570
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
ADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors—A COG study.
First Author: Kara L. Davis
Poster
2023 ASCO Annual Meeting
Prospective phase I study of checkpoint blockade for the treatment of patients with newly diagnosed high-grade glioma prior to radiochemotherapy: Results of nivolumab plus ipilimumab treatment arm.
First Author: Santosh Kesari
Poster
2022 ASCO Annual Meeting
A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study.
First Author: Antonio Calles
Poster
2022 ASCO Annual Meeting
CeNtuRIOn: Rucaparib (R) with nivolumab (N) and ipilimumab (I) in patients (pts) with relapsed ovarian cancer (ROC)—Results of an initial safety cohort.
First Author: Marcia Hall